Cargando…
Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration
BACKGROUND: Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation. Dabigatran (150 mg twice daily) is non-inferior to warfarin for the prevention of stroke and systemic embolism. A dose r...
Autores principales: | Akagi, Yuuki, Chiba, Tatsuo, Uekusa, Shusuke, Kato, Hiroyoshi, Yamamura, Shigeo, Aoki, Yukiko, Enoki, Mizuho, Ogawara, Yuka, Kasahara, Takanori, Kimura, Yuki, Shimizu, Tadahiro, Takeishi, Aiko, Nakajima, Yuko, Kobayashi, Hideki, Sugi, Kaoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670142/ https://www.ncbi.nlm.nih.gov/pubmed/31388437 http://dx.doi.org/10.1186/s40780-019-0145-3 |
Ejemplares similares
-
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022) -
The Dabigatran debate
por: Kaba, Riyaz A, et al.
Publicado: (2014) -
Practical guide to choosing dabigatran 150 mg twice daily or apixaban 5 mg
twice daily for patients with atrial fibrillation
por: Kobayashi, Zen, et al.
Publicado: (2019) -
The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013) -
Dabigatran and apolipoprotein B
por: ten Cate, Hugo
Publicado: (2016)